This editorial reviews imaging modalities for NAFLD/NASH, endorsing PDFF for diagnosing NAFLD and positioning cT1 as the leading biomarker for NASH. It highlights cT1’s utility for identifying patients with ‘at-risk’ NASH (with fibrosis) and for risk-stratifying patients with intermediate or indeterminate results on other guideline-recognized tests (AACE, AGA, DGVS).
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?